ANI Pharmaceuticals, Inc.

ANIP Healthcare Drug Manufacturers Specialty & Generic

ANI Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $883.4 million, up 43.8% from fiscal 2024. In the quarter to June 2026, revenue grew 25.9%, EPS grew 194.6%, free cash flow fell 22.2% and total debt fell 1.78%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

72.08 0.20 −0.28%
Market cap
$1.7B
P/E
14.9×
Fwd P/E
14.5×
Dividend yield
—
F-score
7/9
Altman Z
2.30
Beneish M
−2.62
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
78.34 (18.52) 18.78 (47.90) (42.60) (22.55) 6.09 15.49 (1.08) 3.93
Depreciation & Amortization
91.42 81.33 59.79 59.65 47.25 44.64 44.61 33.74 27.93 22.34
Non Cash Items (Other)
22.59 12.39 15.53 8.34 (1.24) 5.81 9.51 11.87 18.22 11.12
Accounts Receivable Change
(58.53) (21.09) 3.36 (36.91) (5.55) (23.66) (7.29) (4.74) (12.89) (23.96)
Change in inventories
(5.96) (21.29) (5.84) (23.63) 3.22 (2.76) (7.66) (0.38) 5.36 (1.94)
Change in payables and accrued liability
67.69 21.37 28.09 12.60 3.18 0.31 2.02 1.77 2.94 9.99
Income tax paid
(15.53) (1.41) 11.99 (0.16) (7.57) 4.98 (6.10) 6.18 (3.56) 3.53
Change in other assets and liabilities
5.21 11.23 (12.74) (3.20) 6.63 8.50 4.45 3.14 2.50 2.46
Operating Cash Flow
185.23 64.02 118.96 (31.20) 3.32 15.27 45.63 67.07 39.42 27.47
Capital expenditures
(13.83) (2.72) (8.87) (8.13) 0.09 (6.13) (6.63) (5.74) (10.37) (4.57)
Change in intangibles (net)
(20.49) (0.72) (9.64) (7.58) (21.08) (62.19) (20.91) (5.17) (97.62) (144.49)
Net Aquisitions
— (401.28) — (0.03) (84.49) — — (16.47) — —
Investing cash flow
(34.32) (404.72) (18.51) (15.74) (105.48) (68.32) (27.55) (27.38) (107.99) (149.06)
Repayment/Issuance of Debt (Net)
(10.16) 345.22 (3.00) (3.00) 99.02 (0.53) (3.46) (28.94) 75.00 (0.29)
Equity Repurchase (Common, Net)
1.40 (4.47) 84.56 (0.50) 70.76 (0.90) 4.71 2.32 0.09 (1.05)
Equity Repurchase (Preffered, Net)
— — — — 25.00 — — — — —
Dividends Paid (Total)
(1.16) (1.62) (1.62) (1.62) (0.19) — — — — —
Other financial activities
(0.03) (74.18) (12.50) 23.59 (19.38) 19.01 18.64 (1.20) (2.74) 0.32
Financing cash flow
(9.94) 264.95 67.44 (5.13) 194.60 (1.44) 1.25 (27.82) 72.36 (0.73)
Exchange Rate Adjustment
(0.23) (0.47) 0.00 0.00 — — — — — —
Change in Cash
140.73 (76.23) 167.89 (52.07) 92.43 (54.49) 19.33 11.88 3.78 (122.32)
Beginning Cash
144.89 221.12 53.23 105.30 12.87 67.36 48.03 36.15 32.37 154.68
Ending Cash
285.62 144.89 221.12 53.23 105.30 12.87 67.36 48.03 36.15 32.37
Stock Based Compensation
37.93 29.34 20.65 14.60 10.49 12.94 9.22 6.78 6.09 6.07
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
(7.12) (11.18) 24.86 (51.30) (0.08) (12.63) (14.58) 5.97 (5.65) (9.93)
Dividends Paid (Preffered)
(1.16) (1.62) (1.62) (1.62) (0.19) — — — — —
Issuance/Purchase of Shares
1.40 (4.47) 84.56 (0.50) 95.76 (0.90) 4.71 2.32 0.09 (1.05)
Other line items
Revenue per Employee
0.91 0.68 0.76 0.53 0.36 0.56 0.61 0.67 1.02 0.90

Fold the line items

In millions of $ except per-share values · columns are period end dates